BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
화요일, 9월 29

Can Fite Biopharma Ltd

CANFAMEX
Trade with Public
Trade with Public
$2.23
0.0683.15%
가까이에: Sep 28, 5:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리비교주식 보고서

Can Fite Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Can Fite Biopharma (CANF).

Price Target Range — 10 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$144

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Jul 2, 2026HC Wainwright & Co.Swayampakula RamakanthPT RaiseBuy$5→$8
May 13, 2026D. Boral CapitalJason KolbertUpgradeHold→Buy$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $5 to $8.
Benzinga Newsdesk

PRO
D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target

D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy and announces $7 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $2.5 to $5.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and lowers the price target from $11 to $4.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $11 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Can Fite Biofarma at Buy, Announces Price Target of $2.5

HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Can Fite Biofarma (AMEX:CANF) with a Buy rating and announces Price Target of $2.5.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved